{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T18:10:50Z","timestamp":1789409450979,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005205","name":"AstraZeneca Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005205","name":"AstraZeneca Australia.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005205","name":"AstraZeneca Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1025142"],"award-info":[{"award-number":["APP1025142"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.ygyno.2020.04.706","type":"journal-article","created":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T08:14:19Z","timestamp":1588580059000},"page":"47-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort study"],"prefix":"10.1016","volume":"158","author":[{"given":"T.","family":"Sivakumaran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Mileshkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Grant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Na","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"DeFazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Friedlander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Obermair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.M.","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Au-Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2020.04.706_bb0005","unstructured":"Australian Institute of Health and Welfare 2017. Cancer in Australia 2017. Cancer Series No.100. Cat. No. CAN 100. Canberra: AIHW."},{"issue":"Suppl. 3","key":"10.1016\/j.ygyno.2020.04.706_bb0010","first-page":"S3","article-title":"Primary ovarian cancer chemotherapy: current standards of care","volume":"89","author":"WP","year":"2003","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2020.04.706_bb0015","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1093\/jnci\/djj443","article-title":"Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments","volume":"98","author":"Kyrgiou","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2020.04.706_bb0020","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1006\/gyno.2001.6552","article-title":"Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III or IV epithelial ovarian cancer","volume":"85","author":"Covens","year":"2002","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.04.706_bb0025","doi-asserted-by":"crossref","unstructured":"Du Bois A., Quinn M., Thigpen T., Vermorken J., Avall-Lundqvist E., Bookman M., et al. (2005) 2004 Consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 16(Suppl. 8): viii7\u2013viii12.","DOI":"10.1093\/annonc\/mdi961"},{"issue":"2","key":"10.1016\/j.ygyno.2020.04.706_bb0030","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1200\/JCO.1996.14.2.351","article-title":"High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest","volume":"14","author":"Conte","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.04.706_bb0035","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1200\/JCO.2002.20.5.1232","article-title":"Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens","volume":"20","author":"Cant\u00f9","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.04.706_bb0040","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(02)09738-6","article-title":"Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2020.04.706_bb0045","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12885-015-1104-5","article-title":"Retrospective analysis of the impact of platinum dose reduction and chemotherapy delays on the outcomes of stage III ovarian cancer patients","volume":"15","author":"Liutkauskiene","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ygyno.2020.04.706_bb0050","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ygyno.2011.10.003","article-title":"Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer","volume":"124","author":"Nagel","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.04.706_bb0055","doi-asserted-by":"crossref","unstructured":"Olawaiye et al.; Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology\/Gynecologic Oncology Group study, Gynecol Oncol (2018).","DOI":"10.1016\/j.ygyno.2018.07.021"},{"key":"10.1016\/j.ygyno.2020.04.706_bb0060","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/JCO.2006.10.2517","article-title":"Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Winter","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.04.706_bb0065","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ygyno.2005.07.123","article-title":"Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon","volume":"100","author":"Aletti","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.04.706_bb0070","unstructured":"Hryniuk WM. The importance of dose intensity in the outcome of chemotherapy. Important Advances in Oncology 1988. Philadelphia, Pa: JB Lippincott Co; 1988. p. 121\u201341."},{"issue":"24","key":"10.1016\/j.ygyno.2020.04.706_bb0075","doi-asserted-by":"crossref","first-page":"4524","DOI":"10.1200\/JCO.2003.05.002","article-title":"Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices","volume":"21","author":"Lyman","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.04.706_bb0080","doi-asserted-by":"crossref","unstructured":"Terada Y, Nakamae H, Aimoto R, et al. Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma. J Exp Clin Cancer Res. 2009;28(1):116. Published 2009 Aug 19. doi:https:\/\/doi.org\/10.1186\/1756-9966-28-116","DOI":"10.1186\/1756-9966-28-116"},{"issue":"1","key":"10.1016\/j.ygyno.2020.04.706_bb0085","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ygyno.2014.01.030","article-title":"Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS)","volume":"133","author":"Au-Yeung","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2020.04.706_bb0090","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ygyno.2012.12.017","article-title":"Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer","volume":"129","author":"Hanna","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.04.706_bb0095","doi-asserted-by":"crossref","unstructured":"W. P. Tew, J. Java, D. Chi, A. Menzin, J. L. Lovecchio, M. A. Bookman, and S. M. Lichtman. Treatment outcomes for older women with advanced ovarian cancer: results from a phase III clinical trial (GOG182). Journal of Clinical Oncology 2010 28:15_suppl, 5030\u20135030.","DOI":"10.1200\/jco.2010.28.15_suppl.5030"},{"key":"10.1016\/j.ygyno.2020.04.706_bb0100","doi-asserted-by":"crossref","unstructured":"Clamp AR, James EC, McNeish IA, Dean A, Kim J-W, O'Donnell DM, et al. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. The Lancet. 7 D\u00e9c 2019;394(10214):2084\u201395.","DOI":"10.1016\/S0140-6736(19)32259-7"},{"issue":"3","key":"10.1016\/j.ygyno.2020.04.706_bb0105","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/annonc\/mds494","article-title":"A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG","volume":"24","author":"Banerjee","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2020.04.706_bb0110","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0140-6736(09)61157-0","article-title":"Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial","volume":"374","author":"Katsumata","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2020.04.706_bb0115","doi-asserted-by":"crossref","unstructured":"Webb PM, DeFazio A, Obermair A, Grant PT, Friedlander M, Beesley V, Nagle C, OPAL Study Group. The Ovarian cancer Prognosis And Lifestyle (OPAL) study. Journal of Clinical Oncology 2018 36:7_suppl, 88\u201388 DOI: https:\/\/doi.org\/10.1200\/JCO.2018.36.7_suppl.88 Journal of Clinical Oncology 36, no. 7_suppl (March 1 2018) 88\u201388.","DOI":"10.1200\/JCO.2018.36.7_suppl.88"},{"issue":"2","key":"10.1016\/j.ygyno.2020.04.706_bb0120","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3109\/0284186X.2015.1054950","article-title":"Variations in adjuvant chemotherapy and survival in women with epithelial ovarian cancer \u2013 a population-based study","volume":"55","author":"Anuradha","year":"2016","journal-title":"Acta Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2020.04.706_bb0125","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1056\/NEJMoa1505067","article-title":"Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer","volume":"374","author":"Chan","year":"2016","journal-title":"New England Journal of Medicine"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820310167?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820310167?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:50:21Z","timestamp":1758772221000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825820310167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0090825820310167"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.04.706","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.04.706","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2020 Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}